Cite
Role of Kras Status in Patients with Metastatic Colorectal Cancer Receiving First-Line Chemotherapy plus Bevacizumab: A TTD Group Cooperative Study
MLA
Eduardo Díaz-Rubio, et al. “Role of Kras Status in Patients with Metastatic Colorectal Cancer Receiving First-Line Chemotherapy plus Bevacizumab: A TTD Group Cooperative Study.” PLoS ONE, vol. 7, Oct. 2012, p. e47345. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....f4082e5022a58ff509dd9dd99c97af1e&authtype=sso&custid=ns315887.
APA
Eduardo Díaz-Rubio, Auxiliadora Gómez-España, Bartomeu Massutí, Javier Sastre, Margarita Reboredo, José Luis Manzano, Fernando Rivera, M José Safont, Clara Montagut, Encarnación González, Manuel Benavides, Eugenio Marcuello, Andrés Cervantes, Purificación Martínez de Prado, Carlos Fernández-Martos, Antonio Arrivi, Inmaculada Bando, Enrique Aranda, & Spanish Cooperative Group for the Treatment of Digestive Tumors (TTD). (2012). Role of Kras Status in Patients with Metastatic Colorectal Cancer Receiving First-Line Chemotherapy plus Bevacizumab: A TTD Group Cooperative Study. PLoS ONE, 7, e47345.
Chicago
Eduardo Díaz-Rubio, Auxiliadora Gómez-España, Bartomeu Massutí, Javier Sastre, Margarita Reboredo, José Luis Manzano, Fernando Rivera, et al. 2012. “Role of Kras Status in Patients with Metastatic Colorectal Cancer Receiving First-Line Chemotherapy plus Bevacizumab: A TTD Group Cooperative Study.” PLoS ONE 7 (October): e47345. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....f4082e5022a58ff509dd9dd99c97af1e&authtype=sso&custid=ns315887.